- Home
- NEOG vs DNLI Comparison
NEOG vs DNLI Comparison
Compare NEOG & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOG
- DNLI
- Stock Information
- Founded
- NEOG 1981
- DNLI 2013
- Country
- NEOG United States
- DNLI United States
- Employees
- NEOG N/A
- DNLI N/A
- Industry
- NEOG Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEOG Health Care
- DNLI Health Care
- Exchange
- NEOG Nasdaq
- DNLI Nasdaq
- Market Cap
- NEOG 3.2B
- DNLI 3.3B
- IPO Year
- NEOG 1989
- DNLI 2017
- Fundamental
- Price
- NEOG $11.56
- DNLI $21.93
- Analyst Decision
- NEOG Buy
- DNLI Strong Buy
- Analyst Count
- NEOG 2
- DNLI 13
- Target Price
- NEOG $16.25
- DNLI $38.91
- AVG Volume (30 Days)
- NEOG 2.9M
- DNLI 1.1M
- Earning Date
- NEOG 01-10-2025
- DNLI 02-25-2025
- Dividend Yield
- NEOG N/A
- DNLI N/A
- EPS Growth
- NEOG N/A
- DNLI N/A
- EPS
- NEOG N/A
- DNLI N/A
- Revenue
- NEOG $913,828,000.00
- DNLI N/A
- Revenue This Year
- NEOG $3.21
- DNLI N/A
- Revenue Next Year
- NEOG $4.80
- DNLI $651.24
- P/E Ratio
- NEOG N/A
- DNLI N/A
- Revenue Growth
- NEOG N/A
- DNLI 204.74
- 52 Week Low
- NEOG $10.72
- DNLI $14.56
- 52 Week High
- NEOG $18.58
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- NEOG 38.62
- DNLI 51.28
- Support Level
- NEOG $10.72
- DNLI $18.52
- Resistance Level
- NEOG $12.98
- DNLI $22.37
- Average True Range (ATR)
- NEOG 0.67
- DNLI 1.31
- MACD
- NEOG -0.03
- DNLI 0.31
- Stochastic Oscillator
- NEOG 31.23
- DNLI 88.57
About NEOG Neogen Corporation
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.